Erratum
Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Shiraz Jamshaid(Hammersmith Hospital), Francesco Dieli(University of Palermo), Anjeza Xholli(Ospedale Policlinico San Martino), Koji Teraishi, Veronica Medici(University of Modena and Reggio Emilia), José Guillen-Rodriguez, Angela Musella, Angela Toss(University of Modena and Reggio Emilia), Alessia Romito, Yu Nakaji, Elisabetta De Matteis(Unknown), Massimo Federico(University of Modena and Reggio Emilia), Kara Heard, Lora Inclán, Xavier Rivera(University of Arizona), Serena Maria Boccia, Koji Ando(Tokyo Woman's Christian University), Giuseppe Cicero(University of Palermo), Ludovico Muzii(Università Campus Bio-Medico), Kippei Ohgaki, Angelo Cagnacci(Ospedale Policlinico San Martino), Marco Monti, Eiji Oki(Kyushu University), Jonathan H. Schatz(University of Miami), Yoko Zaitsu(Japanese Foundation For Cancer Research), Rossella De Luca(Istituti di Ricovero e Cura a Carattere Scientifico), Pierluigi Benedetti Panici(Policlinico Umberto I), Laura Vertechy, Cláudia Marchetti(Sapienza University of Rome), Daniel O. Persky(Universidad San Carlos), Nami Yamashita(Dana-Farber Cancer Institute), Marco Merli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Violante Di Donato(Policlinico Umberto I), Giannina Contu, Innocenza Palaia(Policlinico Umberto I), Giovanni Grandi(University of Modena and Reggio Emilia), Isabella Marchi(University of Modena and Reggio Emilia), Hiroshi Saeki, Yoshinao Oda(Kyushu University), Yuichiro Nakashima, Monika Schmelz, Masahiko Sugiyama, Shinji Okano, Francesca De Felice(Policlinico Umberto I), Yoshihiko Maehara, Yuichiro Umemoto, David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessia Dalla Pria, Soham D. Puvvada(University of Arizona)
Cited by 0
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743